Alzheimer's disease clinical trials with select modalities worldwide as of 2019
This statistic depicts the percentage of Alzheimer's disease clinical trials with select modalities as of 2019. According to the data, 53 percent of Alzheimer's disease clinical trials had small molecule sizes at that time. Modality is an important measure of how a drug can be delivered and administered. The term modality refers to the size of the molecules used in the drug.
